Brazilian pediatrician Monica Levy, one of the volunteers who received the COVID-19 vaccine, works at the Infectious and Parasitic Diseases and Immunization Clinic (CEDIPI), in São Paulo, Brazil, on July 24, 2020. The doctor is one of 5,000 volunteers in Brazil who participated in the trials The third – last phase before homogenization – the ChAdOx1 nCoV-19 vaccine, developed by the University of Oxford with the British pharmaceutical company AstraZeneca.
Nelson Almeida | Agence France-Presse | Getty Images
London – The Coronavirus vaccine, developed by the Universities of Oxford and AstraZeneca, is safe and causes a similar immune response among all adults, according to preliminary results from a peer-reviewed phase II trial.
The promising early results were published in The Lancet, one of the world’s largest medical journals, on Thursday.
The study of 560 healthy adults, including 240 over the age of 70, found the vaccine was safe and produced a similar immune response among people over the age of 56 and those between the ages of 18 and 55.
Old people facebig dangerThe World Health Organization said: “Of contracting a serious illness when contracting Covid-19, citing reduced immune function and possible underlying health conditions. However, people of all ages are at risk of contracting the virus.
The British pharmaceutical giant AstraZeneca, which is working in cooperation with the University of Oxford, has it He previously said Interim data showed that their experimental vaccine produced an immune response in older and younger adults.
A safe and effective vaccine is seen by many as a game-changer in the battle against the coronavirus pandemic, which has killed more than 1.3 million people worldwide.
There are still huge challenges before a vaccine is introduced. The global battle to secure potential supplies Alarm triggered About fair access, while Questions remain On logistics, distribution and cost.
The Oxford candidate vaccine has been found to cause few side effects and trigger immune responses in both parts of the immune system in all age groups, with standardized low doses.
Preliminary results showed that the vaccine – ChAdOx1 nCoV-19 – stimulated what is known as a “T-cell response” within 14 days of the first dose, and an antibody response within 28 days of the booster dose. Scientists expect that T-cell responses play a role in long-term immunity to the virus.
Dr Mahshi Ramasamy, a co-author of the study at the University of Oxford, said that the antibody and T-cell responses among the elderly were “robust” and “encouraging”.
“Populations at risk of contracting the dangerous disease COVID-19 include people with existing health conditions and the elderly,” said Ramasamy.
“We hope this means that our vaccine will help protect some of the most vulnerable people in society, but more research will be needed before we can be sure.”
The authors of the Oxford study said their results could be encouraging if immune responses are found to be linked to protection against COVID-19 infection. The Phase 2 trial has not assessed the efficacy of the vaccine, however, phase III trials are underway to confirm this.
Results are expected later this year depending on the rate of infection within the clinical trial communities.
The authors noted some limitations of their study, including that participants in the older age group had an average age of 73 to 74 years and had few underlying health conditions, and nearly all of the participants were white and non-smoking.
People from a range of backgrounds, countries and ethnicities were said to have been included in the third phase of the trial.
The study comes days after two other vaccine makers reported encouraging results from phase III trials. They said their experimental vaccines have proven to be very effective in protecting against the Coronavirus, boosting optimism at a time when health systems in Europe and the United States are once again on the verge of breaking.
Pfizer and BioNTech said on Wednesday that the final analysis found their candidate vaccine was 95% efficiency In preventing Covid-19 and appears to prevent severe disease. Earlier this week, Moderna said data for the initial phase three of the trials showed that its vaccine was 94.5% effective.